PTC Therapeutics (NASDAQ: PTCT) has recently received a number of price target changes and ratings updates:

  • 9/29/2017 – PTC Therapeutics had its “sector perform” rating reaffirmed by analysts at Royal Bank Of Canada.
  • 9/29/2017 – PTC Therapeutics had its price target lowered by analysts at Barclays PLC from $22.00 to $15.00. They now have an “equal weight” rating on the stock.
  • 9/27/2017 – PTC Therapeutics had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a $28.00 price target on the stock.
  • 9/26/2017 – PTC Therapeutics had its “outperform” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $25.00 price target on the stock.
  • 9/26/2017 – PTC Therapeutics had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 9/8/2017 – PTC Therapeutics had its “hold” rating reaffirmed by analysts at Barclays PLC. They now have a $22.00 price target on the stock.
  • 9/7/2017 – PTC Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 8/30/2017 – PTC Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $23.00 price target on the stock. According to Zacks, “PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. “
  • 8/23/2017 – PTC Therapeutics is now covered by analysts at William Blair. They set a “market perform” rating and a $17.00 price target on the stock.
  • 8/17/2017 – PTC Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

PTC Therapeutics, Inc. (PTCT) traded down 1.36% on Friday, reaching $19.63. 505,354 shares of the company’s stock were exchanged. The company’s market cap is $810.80 million. PTC Therapeutics, Inc. has a 12-month low of $4.03 and a 12-month high of $22.00. The firm has a 50 day moving average of $19.54 and a 200-day moving average of $16.05.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.45. The business had revenue of $47.96 million for the quarter, compared to analyst estimates of $28.78 million. PTC Therapeutics had a negative net margin of 36.44% and a negative return on equity of 51.81%. The company’s quarterly revenue was up 206.9% on a year-over-year basis. During the same period in the prior year, the business earned ($1.14) earnings per share. Equities analysts expect that PTC Therapeutics, Inc. will post ($2.34) EPS for the current fiscal year.

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Receive News & Ratings for PTC Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.